You are in: eMedicine Specialties > Neurology > Sleep-Related Diseases Sleep Dysfunction in WomenArticle Last Updated: Jun 29, 2007AUTHOR AND EDITOR INFORMATIONAuthor: Gila Hertz, PhD, ABSM, Director, Center for Insomnia and Sleep Disorders, Clinical Associate Professor of Psychiatry and Behavioral Sciences, State University of New York at Stony Brook Gila Hertz is a member of the following medical societies: American Academy of Sleep Medicine and American Psychological Association Coauthor(s): Mary E Cataletto, MD, Associate Director, Division of Pediatric Pulmonology, Winthrop University Hospital; Associate Professor, Department of Clinical Pediatrics, State University of New York at Stony Brook; Gabriele M Barthlen, MD, Assistant Professor, Department of Neurology, Cornell University; Director of Sleep-Wake Disorders Center, Department of Neurology, New York Presbyterian Hospital Editors: Carmel Armon, MD, MSc, MHS, Professor of Neurology, Tufts University School of Medicine; Chief, Division of Neurology, Baystate Medical Center; Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine; Norberto Alvarez, MD, Assistant Professor, Department of Neurology, Harvard Medical School; Consulting Staff, Department of Neurology, Boston Children's Hospital; Matthew J Baker, MD, Consulting Staff, Collier Neurologic Specialists, Naples Community Hospital; Nicholas Lorenzo, MD, Chief Editor, eMedicine Neurology; Consulting Staff, Neurology Specialists and Consultants Author and Editor Disclosure Synonyms and related keywords: insomnia, sleep disorders, sleep-onset insomnia, sleep-maintenance insomnia, circadian rhythm, sleep-disordered breathing, upper airway resistance syndrome, UARS, obstructive sleep apnea, OSA, restless legs syndrome, RLS, periodic limb movement disorder, PLMD, narcolepsy, parasomnias, premenstrual syndrome, PMS, sleep deprivation, sleep hygiene, snoring, fatigue, pregnancy-related sleep disorder, menstrual cycle and sleep INTRODUCTIONBackgroundWomen are twice as likely as men to have difficulties falling asleep or maintaining sleep. Yet, physicians often overlook women's complaints about sleep. Scientific research only recently has focused on the incidence and causes of sleep problems in women, particularly sleep patterns and the changing needs and problems associated with sleep throughout women's life spans. In general, sleep is sounder and less prone to disturbances during young adulthood; however, some women are prone to sleep problems during their reproductive years. Hormonal fluctuations associated with menstrual cycle and pregnancy may affect circadian rhythms and stress reactivity, thereby rendering women more vulnerable to emotional stress and to concomitant sleep disturbances. For other women, psychosocial factors pose certain challenges. Many young women coping with work as well as with their roles as mothers and wives may cut back on their sleep, ignoring signs of fatigue and other effects of insufficient sleep. As women age, physical and hormonal changes take place that make sleep lighter and less sound. Older women get less deep sleep and are more likely to wake up at night. Physical factors, such as physical discomfort, pain, disorders of breathing, and menopausal symptoms may also disturb sleep. Studies have shown that about 30% of employed women report having problems with their sleep, and the problems are more frequent in women older than 40 years. Getting enough sleep has an enormous impact on a woman's life as it improves job performance, concentration, social interaction, and general sense of well-being. Definitions and terminology
PathophysiologyIn general, sex steroids play a role in the etiology of sleep disorders in women, either by having a direct effect on sleep processes or through their effect on mood and emotional state. Sex steroids influence EEG sleep during the luteal phase by increasing the EEG frequency and core body temperature. Lack of estrogen, later in life, contributes to vasomotor symptoms, including hot flashes that cause sleep disturbances. Decreased estrogen also plays a role in the etiology of sleep apnea. Pathophysiologic factors in some of the major sleep disorders seen in women are as follows: Sleep-disordered breathing: This involves various degrees of pharyngeal obstruction ranging from UARS to OSA. Obstruction results from high negative pressure generated by the inspiratory effort and failure of the dilating upper airway muscles to maintain airway patency. Contributing factors are degree of muscle atonia and various anatomical abnormalities that increase airway occlusion (eg, enlarged tonsils, macroglossia). The nature of OSA in menopausal women is different than that of age-matched men. Women demonstrate more partial obstructive events (eg, hypopneas) than complete OSAs. In addition, the duration of hypopneas, when present, tends to be shorter in women than in men. Regardless of age, OSA is less severe in women than in men. A possible explanation is the effect of a female hormone (probably progesterone) on the activity of the dilator muscle of the pharynx. In a recent study, performed in healthy women with regular menstrual cycles, upper airway resistance was found to be lower during the luteal phase of the menstrual cycle compared to the follicular phase. Progesterone levels are elevated during the luteal phase. Restless Legs Syndrome (RLS) and Periodic Limb Movement Disorder (PLMD): These are idiopathic disorders that can cause profound disruption. RLS, a waking disorder that usually occurs before sleep onset, is associated with discomfort in the calves causing restlessness in the legs, which is relieved by movement. PLMD, occurring during sleep, involves isolated periodic movements of the lower limbs, usually followed by arousal from sleep. In severe cases, frequent leg movements can cause significant sleep interruption, resulting in complaints of insomnia or excessive sleepiness. Narcolepsy: The 4 major features of narcolepsy are (1) daytime sleepiness, (2) hypnagogic hallucinations, (3) cataplexy, and (4) sleep paralysis. These features are related closely to features normally occurring exclusively during rapid eye movement (REM) sleep. The symptom of cataplexy, for example, which involves sudden loss of muscle tone during waking hours, is identical to muscle paralysis normally experienced during REM sleep. Thus, narcolepsy has been hypothesized to represent a dissociative process of REM sleep mechanisms and an intrusion of these mechanisms into waking hours. FrequencyUnited StatesThe difficulty most frequently reported by women is insomnia. As many as 80% of women report premenstrual symptoms that include insomnia. However, only 10-15% of women experience premenstrual dysphoric disorder (PMDD). About two thirds of perimenopausal women have sleep-related problems. Menopausal and postmenopausal women are more likely to report frequent insomnia (56%) than premenopausal (49%) women and also are more likely to use a prescription sleep aid (20%) than premenopausal women (8%). The prevalence of pathological SDB has been estimated at 5.2% for women aged 40-64. Over 30% of elderly persons demonstrate at least mild sleep-related breathing abnormalities, as defined by an apnea/hypopnea index of 5 or greater. Postmenopausal women are 2.6 times more likely than premenopausal women to have an apnea-hypopnea index (AHI) greater than 5. The incidence and prevalence of SDB during pregnancy is unknown. Generally, sleep studies have found no evidence of significant SDB during pregnancy, possibly reflecting increased circulating levels of progesterone. The prevalence of PLMD increases significantly with age. Studies have estimated that as many as 45% of the independently living population older than 65 years show the minimal criteria for diagnosis of PLMD. The prevalence of RLS has been reported at 10% for those aged 30-79 years. No gender difference exists in the prevalence of RLS. Smoking, diabetes mellitus, pregnancy, greater age, and greater body mass index significantly increase the incidence of RLS. InternationalEstimated prevalence of SDB in a study from Iceland has been reported at 2.5% for women aged 40-59. Mortality/Morbidity
RaceThe prevalence of obesity is higher in black women than in white women. Obesity places women at higher risk of developing OSA, particularly after menopause. Sleep apnea is pervasive in non-European–American women. Compared with European–American women, non-European–American women have more blood oxygen desaturations during sleep. SexThe prevalence of sleep-disordered breathing (SDB) is significantly higher in young men than in young women. However, the chance of women older than 50 years developing sleep apnea may be equal to that of men. The prevalence is very high (may exceed 50%) in both older women and men. Age
CLINICALHistoryTaking a careful sleep history is an essential part of the evaluation of sleep disorders. This is particularly important for women who present with insomnia, as insomnia constitutes a symptom rather than a disorder and may be related to various problems, including psychiatric and medical conditions. Accurate differential diagnosis is essential before formulation of a treatment plan. The nature of the difficulty, the duration of symptoms, medical and psychiatric history, and careful assessment of current and previous sleep patterns are all essential pieces of information in the differential diagnosis.
PhysicalThe examination of the woman presenting with sleep problems addresses 2 major issues: psychological and physiological findings. General appearance and affect can be assessed early and during the examination. Chronic illness or chronic pain often is evinced in the general appearance and movement of a patient. The examination focuses on addressing any major medical illness that may be associated with sleep symptomatology, as well as on risk factors that direct toward evaluation of sleep-related disorders such as narcolepsy and OSA. Many patients with circadian rhythm disorders and insomnia may have normal physical examination findings.
CausesMajor factors that play a role in causing sleep disturbances in women include the following:
DIFFERENTIALSInsomnia Narcolepsy Obstructive Sleep Apnea-Hypopnea Syndrome REM Sleep Behavior Disorder Sleeplessness and Circadian Rhythm Disorder
|
| Drug Name | Zolpidem (Ambien, Ambien CR) |
|---|---|
| Description | DOC for treatment of primary insomnia (ie, sleep-onset insomnia). Indicated for acute short-term insomnia for duration that does not exceed a few weeks. The extended-release product (Ambien CR) consists of a coated 2-layer tablet and is useful for insomnia characterized by difficulties with sleep onset and/or sleep maintenance. The first layer releases drug content immediately to induce sleep; the second layer gradually releases additional drug to provide continuous sleep. |
| Adult Dose | 10 mg PO hs Extended-release: 12.5 mg PO hs Extended-release in elderly patients: 6.25 mg PO hs |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity; lactation |
| Interactions | Increases toxicity of alcohol and CNS depressants; effect may be delayed if taken with food or shortly after a meal |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Monitor elderly for impaired cognitive or motor performance; extended-release dosage form must be swallowed whole (do not divide, chew, or crush) |
| Drug Name | Zaleplon (Sonata) |
|---|---|
| Description | A pyrazolopyrimidine, indicated for short-term treatment of difficulties in falling asleep. Should be used for 7-10 d. Has been shown to cause minimal daytime grogginess. |
| Adult Dose | 5-10 mg PO hs |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity |
| Interactions | Cimetidine significantly increases levels |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Failure of insomnia to remit after 7-10 d of treatment may indicate need for evaluation of primary psychiatric or medical illness; limit treatment to 7-10 d of use, and reevaluate patient if to be taken for >2-3 wk (do not prescribe in quantities exceeding 1-mo supply); in hepatic function impairment, reduce dose to 5 mg PO hs; caution in patients exhibiting signs or symptoms of depression |
| Drug Name | Eszopiclone (Lunesta) |
|---|---|
| Description | Nonbenzodiazepine hypnotic pyrrolopyrazine derivative of the cyclopyrrolone class. The precise mechanism of action is unknown but is believed to interact with GABA-receptor at binding domains close to or allosterically coupled to benzodiazepine receptors. Indicated for insomnia to decrease sleep latency and improve sleep maintenance. Short half-life of 6 h. Higher doses (ie, 2 mg for elderly adults and 3 mg for nonelderly adults) are more effective for sleep maintenance, whereas lower doses (ie, 1 mg for elderly adults and 2 mg for nonelderly adults) are suitable for difficulty in falling asleep. |
| Adult Dose | Nonelderly adults: 2 mg PO hs; may increase to 3 mg PO hs prn Elderly adults: 1 mg PO hs initially; not to exceed 2 mg PO hs Severe hepatic impairment: Do not exceed 2 mg PO hs |
| Pediatric Dose | <18 years: Not established >18 years: Administer as in adults |
| Contraindications | Documented hypersensitivity |
| Interactions | CYP3A4 and CYP2E1 substrate; potent CYP3A4 inhibitors (eg, ketoconazole, itraconazole, clarithromycin, nefazodone, ritonavir, nelfinavir) increases AUC, Cmax, and t1/2 and therefore potential toxicity (decrease dose); potent CYP3A4 inducers (eg, rifampicin) increase clearance; coadministration with alcohol or other CNS depressants may increase effect and toxicity (decrease dose); coadministration with olanzapine may decrease DSST scores; sleep onset may be delayed if taken with or immediately after a high-fat or heavy meal |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | May cause dysgeusia, headache, or coldlike symptoms; rare adverse effects associated with hypnotics include short-term amnesia, confusion, agitation, hallucinations, worsened depression, or suicidal thoughts; high doses (ie, 6-12 mg) produce euphoric effects similar to those of diazepam 20 mg; anxiety, abnormal dreams, nausea, and upset stomach may occur within 48 h after discontinuing; alertness may be affected the following day, use caution while operating machinery or driving a car |
Estrogen replacement has been shown to improve sleep in menopausal women, primarily by reducing vasomotor symptoms that disturb sleep. In addition, may improve sleep-related breathing disorders. Studies have shown that estrogen, either alone or combined with progestin (but not progestin alone), markedly reduced OSA in menopausal women. Oral Premarin is an example of an oral estrogen replacement. The choice of HRT should be made on an individual basis in consultation with a gynecologist.
| Drug Name | Conjugated estrogens (Premarin) |
|---|---|
| Description | Multiple aspects of menopause respond to estrogen replacement therapy, including vasomotor symptoms and atrophic vaginitis. However, has not been shown effective in treating depression associated with menopause. Decisions for HRT should be made on individual basis in consultation with gynecologist. Dosing may need to be titrated individually, and each patient monitored for risks and adverse effects. Premarin available in tablet form for oral administration in strengths of 0.3 mg, 0.625 mg, 0.9 mg, 1.25 mg, and 2.5 mg. |
| Adult Dose | 0.3-1.25 mg PO; use lowest possible effective dose |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity; known or suspected pregnancy; breast cancer; undiagnosed abnormal genital bleeding; active thrombophlebitis or thromboembolic disorders; history of thrombophlebitis, thrombosis; or thromboembolic disorders associated with previous estrogen use (except when used in treatment of breast or prostatic malignancy) |
| Interactions | May reduce hypoprothrombinemic effect of anticoagulants; barbiturates, rifampin, and other agents that induce hepatic microsomal enzymes may reduce levels; pharmacologic and toxicologic effects of corticosteroids may occur as result of estrogen-induced inactivation of hepatic P-450 enzyme; hydantoins may result in loss of seizure control |
| Pregnancy | X - Contraindicated in pregnancy |
| Precautions | While weight gain, peripheral edema, and breast tenderness are among more frequent adverse effects, patients should be advised to notify their gynecologist of any breast masses, depression, or changes in vaginal bleeding and their internist if they have any chest pain, tingling, or shortness of breath; advise patient to avoid exposure to prolonged or direct sunlight and not to skip doses or alter regimen without consulting physician |
Selective serotonin reuptake inhibitors (SSRIs) are generally well tolerated and are currently the most frequently prescribed drugs for treatment of depression. Pharmacologic treatment with antidepressants is indicated for PMDD, postpartum depression, and clinical depression in patients of any age.
Serotonin noradrenaline reuptake inhibitors (SNRIs) are also used. These agents exhibit both noradrenergic and serotonergic effects in patients with depression.
| Drug Name | Sertraline (Zoloft) |
|---|---|
| Description | Effective for treatment of clinical depression in women. Also indicated for panic disorders and obsessive-compulsive disorders. |
| Adult Dose | 50 mg/d PO |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity; concurrent MAOIs |
| Interactions | Increases toxicity of MAOIs, diazepam, tolbutamide, and warfarin; serotonin syndrome (ie, myoclonus, rigidity, confusion, nausea, hyperthermia, autonomic instability, coma, eventual death) occurs with simultaneous use of other serotonergic agents (eg, anorectic agents, tramadol, buspirone, trazodone, clomipramine, nefazodone, tryptophan), discontinue other serotonergic agents at least 2 wk prior to SSRIs |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Caution in preexisting seizure disorders, recent myocardial infarction, unstable heart disease, or hepatic or renal impairment |
| Drug Name | Escitalopram oxalate (Lexapro) |
|---|---|
| Description | Insomnia associated with depression. Selective serotonin reuptake inhibitor (SSRI) and S-enantiomer of citalopram. Used for the treatment of depression. Mechanism of action is thought to be potentiation of serotonergic activity in central nervous system resulting from inhibition of CNS neuronal reuptake of serotonin. Onset of depression relief may be obtained after 1-2 wk, which is sooner than other antidepressants. |
| Adult Dose | 10 mg PO daily without regard to meal; may titrate up to 20 mg qd |
| Pediatric Dose | <18 years: Not established >18 years: Administer as in adults |
| Contraindications | Documented hypersensitivity; administration within 14 d of receiving MAOI |
| Interactions | Primarily metabolized by CYP450 3A4 and 2C19; coadministration with alcohol or other centrally acting drugs increases CNS depression; cimetidine increases AUC and maximum serum concentration; coadministration with sumatriptan and SSRIs has caused weakness and hyperreflexia |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Elderly persons have decreased clearance; cognitive and motor function (use caution operating motor vehicles and heavy materials); depression may worsen; suicides have been reported; seizures; activation of mania/hypomania; lactation; physician must be consulted before other medications are added or used |
| Drug Name | Fluoxetine hydrochloride (Sarafem) |
|---|---|
| Description | Approved recently for treatment of PMDD. Indicated for treatment of premenstrual insomnia associated with PMDD. |
| Adult Dose | 20 mg PO qd |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity; MAOIs within last 2 wk |
| Interactions | Increases toxicity of diazepam and trazodone by decreasing clearance; increases toxicity of MAOIs and highly protein-bound drugs; serotonin syndrome (ie, myoclonus, rigidity, confusion, nausea, hyperthermia, autonomic instability, coma, eventual death) occurs with simultaneous use of other serotonergic agents (eg, anorectic agents, tramadol, buspirone, trazodone, clomipramine, nefazodone, tryptophan), discontinue other serotonergic agents at least 2 wk prior to SSRIs |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Caution in hepatic impairment and history of seizures; MAOIs should be discontinued at least 14 d before initiating fluoxetine therapy |
| Drug Name | Mirtazapine (Remeron) |
|---|---|
| Description | Relatively new antidepressant, not as widely used as sertraline. Exhibits both noradrenergic and serotonergic activity. In cases of depression associated with severe insomnia and anxiety, has been shown superior to other SSRI drugs. |
| Adult Dose | 15 mg (range 15-30 mg) PO hs initially; increase if necessary |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity; MAOIs within past 14 d |
| Interactions | May increase effect of CNS depressants; concurrent MAOIs may trigger hypertensive crisis |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | May cause drowsiness; discontinue use if patient develops sore throat, fever, or other signs of infection; suicide ideation inherent in depression and may persist until significant remission occurs; severe neutropenia reported in clinical trials |
These agents may be effective in narcolepsy.
| Drug Name | Modafinil (Provigil) |
|---|---|
| Description | Mechanism(s) of action in wakefulness unknown. Has wake-promoting actions like sympathomimetic agents. |
| Adult Dose | 200 mg PO qd |
| Pediatric Dose | <16 years: Not established >16 years: Administer as in adults |
| Contraindications | Documented hypersensitivity |
| Interactions | May decrease levels of cyclosporine or steroidal contraceptives, and to lesser degree, theophylline; may increase concentrations of diazepam, propranolol, and phenytoin |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Monitor patients closely for signs of misuse or abuse, especially those with history of abuse of drugs or stimulants such as methylphenidate, amphetamine, and cocaine |
| Drug Name | Armodafinil (Nuvigil) |
|---|---|
| Description | R-enantiomer of modafinil (mixture of R- and S-enantiomers). Elicits wake-promoting actions similar to sympathomimetic agents, although pharmacologic profile is not identical to sympathomimetic amines. In vitro, binds dopamine transporter and inhibits dopamine reuptake. Not a direct- or indirect-acting dopamine receptor agonist. Indicated to improve wakefulness in individuals with excessive sleepiness associated with narcolepsy, obstructive sleep apnea-hypopnea syndrome (OSAHS), or shift-work sleep disorder. |
| Adult Dose | Narcolepsy: 150-250 mg PO qam OSAHS: 150 mg PO qam; may increase dose, not to exceed 250 mg/d Shift work: 150 mg PO administered 1 h before start of work shift |
| Pediatric Dose | <17 years: Not established >17 years: Administer as in adults |
| Contraindications | Documented hypersensitivity |
| Interactions | Weakly induces CYP1A2 and CYP3A; may decrease levels of drugs metabolized by CYP1A2 (eg, theophylline) and CYP3A (eg, cyclosporine, midazolam, triazolam, steroidal contraceptives); may inhibit CYP2C19 activity, thereby increasing serum levels of CYP2C19 substrates (eg, omeprazole, phenytoin, propranolol) |
| Pregnancy | C - Safety for use during pregnancy has not been established |
| Precautions | Caution in hepatic impairment and decrease dose with severe hepatic impairment; serious rash, including Stevens-Johnson syndrome, has been reported; other serious hypersensitivity reactions include angioedema, anaphylactoid reactions, and multiorgan hypersensitivity reactions; psychiatric adverse events (eg, mania, delusions, hallucinations, suicidal ideation) have been reported with modafinil; may increase blood pressure; monitor patients closely for signs of misuse or abuse, especially those with a history of drug or stimulant abuse (eg, methylphenidate, amphetamine, or cocaine) |
Dopamine agonists may be effective for treatment of restless legs syndrome.
| Drug Name | Pramipexole (Mirapex) |
|---|---|
| Description | Nonergot dopamine agonist with specificity of D2 dopamine receptor, but also has been shown to bind to D3 and D4 receptors and may stimulate dopamine activity on nerves of striatum and substantia nigra. |
| Adult Dose | 0.125-1 mg PO hs initially, increase prn |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity |
| Interactions | Cimetidine may increase toxicity; increases levodopa levels |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Caution in renal insufficiency and preexisting dyskinesias |
Indicated for insomnia characterized by difficulty with sleep onset.
| Drug Name | Ramelteon (Rozerem) |
|---|---|
| Description | Melatonin receptor agonist with high selectivity for human melatonin MT1 and MT2 receptors. MT1 and MT2 are thought to promote sleep and be involved in maintenance of circadian rhythm and normal sleep-wake cycle. |
| Adult Dose | 8 mg PO 30 min before bedtime on empty stomach |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity; strong cytochrome P450 CYP1A2 inhibitors (eg, fluvoxamine); severe hepatic impairment |
| Interactions | Major substrate of cytochrome P450 CYP1A2 and minor substrate of CYP2C and CYP3A4; strong CYP1A2 inhibitors (eg, fluvoxamine) increase AUC up to 190-fold and Cmax 70-fold; strong CYP inducers (eg, rifampin) decrease total exposure by mean of 80%; strong CYP3A4 inhibitors (eg, ketoconazole) and strong CYP2C9 inhibitors (eg, fluconazole) may increase serum levels |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Caution with mild hepatic impairment; adverse effects leading to discontinuation in clinical trials included dizziness, nausea, fatigue, headache, and worsening insomnia |
These agents have been the hypnotics of choice for many years because of their relative safety compared to barbiturates. By binding to specific receptor sites, these agents appear to potentiate the effects of GABA and facilitate inhibitory GABA neurotransmission and other inhibitory transmitters.
Benzodiazepines are used when additional anxiolytic effects are desired in addition to hypnotic effects. Intermediate and long-acting benzodiazepines are used for sleep-maintenance insomnia.
| Drug Name | Triazolam (Halcion) |
|---|---|
| Description | Short acting; good agent for sleep-onset insomnia; has no significant residual effects in morning. |
| Adult Dose | 0.125-0.25 mg PO hs; 0.125 mg PO hs in elderly persons |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity; narrow-angle glaucoma; untreated obstructive sleep apnea; history of substance abuse |
| Interactions | Phenothiazines, barbiturates, alcohols, and MAOIs increase CNS toxicity |
| Pregnancy | D - Unsafe in pregnancy |
| Precautions | High incidence of rebound insomnia; adverse effects include dizziness, drowsiness, and headache, all of which are dose related; use cautiously in depressed patients; caution and close monitoring needed in hepatic dysfunction, low albumin levels, renal or pulmonary disease; may cause residual daytime sedation, impair cognition, and increase risk of falls, especially in older people |
| Drug Name | Estazolam (ProSom) |
|---|---|
| Description | Intermediate acting with slow onset of action and long duration; good agent for sleep-maintenance insomnia. |
| Adult Dose | 1-2 mg PO hs; 0.5-1 mg PO hs in elderly persons |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity; narrow-angle glaucoma; untreated obstructive sleep apnea; history of substance abuse |
| Interactions | Phenothiazines, barbiturates, alcohols, and MAOIs increase CNS toxicity |
| Pregnancy | D - Unsafe in pregnancy |
| Precautions | Caution in depressed patients; most common adverse effects include drowsiness, hypokinesia, dizziness, and abnormal coordination; may have more significant respiratory depressive effects than other agents in its class; caution and close monitoring needed in hepatic dysfunction, low albumin levels, renal or pulmonary disease; may cause residual daytime sedation, impair cognition, and increase risk of falls, especially in older people |
| Drug Name | Temazepam (Restoril) |
|---|---|
| Description | Indicated for both sleep-onset and maintenance insomnia. Should be taken at bedtime to prevent daytime aftereffects. |
| Adult Dose | <60 years: 15-30 mg/d PO qhs >60 years: Use lower doses |
| Pediatric Dose | Not recommended |
| Contraindications | Documented hypersensitivity; narrow-angle glaucoma; untreated OSA; history of substance abuse; severe uncontrolled pain |
| Interactions | Phenothiazines, barbiturates, alcohols, and MAOIs increase toxicity |
| Pregnancy | D - Unsafe in pregnancy |
| Precautions | Caution with other CNS depressants, low albumin levels, or hepatic disease (may increase toxicity) |
These agents may be effective for moderate-to-severe primary RLS. Neuropharmacological evidence suggests primary dopaminergic system involvement in RLS.
| Drug Name | Ropinirole hydrochloride (Requip) |
|---|---|
| Description | Second-generation, nonergoline dopamine agonist that directly stimulates dopamine receptors in brain. Has high specificity for D3 receptor subtype. Indicated for moderate-to-severe RLS. Take at bedtime. |
| Adult Dose | Administer once daily, 1-3 h before bedtime; after 2 d, may gradually titrate dose upward to desired effect according the following schedule: Days 1-2: 0.25 mg PO hs Days 3-7: 0.5 mg PO hs Week 2: 1 mg PO hs Week 3: 1.5 mg PO hs Week 4: 2 mg PO hs Week 5: 2.5 mg PO hs Week 6: 3 mg PO hs Week 7: 4 mg PO hs |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity |
| Interactions | Estrogens may reduce clearance by 36%; dose adjustment may be required if estrogen therapy stopped or started during treatment; potential exists for substrates or inhibitors of CYP1A2 to alter clearance; if therapy with potent CYP1A2 inhibitor stopped or started during treatment, dose adjustments may be necessary; dopamine antagonists (eg, phenothiazines, butyrophenones, thioxanthenes, metoclopramide) may diminish effectiveness; coadministration with sedatives and other CNS depressants may cause additive sedation |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Monitor for signs and symptoms of orthostatic hypotension; dopamine receptor agonists may potentiate adverse dopaminergic effects of levodopa and may cause or exacerbate preexisting dyskinesia (decreasing levodopa dose may ameliorate this adverse effect); retroperitoneal fibrosis, pulmonary infiltrates, pleural effusion, and pleural thickening have occurred in some patients treated with ergot-derived dopaminergic agents; complete resolution of these complications does not always occur when drug is discontinued; may cause patients to fall asleep or feel very sleepy while doing normal activities (eg, driving); common adverse effects while treating RLS include nausea, somnolence, vomiting, dizziness, and fatigue |